664 related articles for article (PubMed ID: 12605972)
1. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial.
Yeoh EE; Holloway RH; Fraser RJ; Botten RJ; Di Matteo AC; Butters J; Weerasinghe S; Abeysinghe P
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1072-83. PubMed ID: 16965866
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.
Yeoh EE; Botten RJ; Butters J; Di Matteo AC; Holloway RH; Fowler J
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1271-8. PubMed ID: 20934277
[TBL] [Abstract][Full Text] [Related]
4. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
[TBL] [Abstract][Full Text] [Related]
5. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
6. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
7. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect.
Lee WR; Hanks GE; Hanlon AL; Schultheiss TE; Hunt MA
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):251-7. PubMed ID: 8635930
[TBL] [Abstract][Full Text] [Related]
8. Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities.
Nihei K; Ogino T; Onozawa M; Murayama S; Fuji H; Murakami M; Hishikawa Y
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):390-6. PubMed ID: 20832180
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.
Hoffman KE; Skinner H; Pugh TJ; Voong KR; Levy LB; Choi S; Frank SJ; Lee AK; Mahmood U; McGuire SE; Schlembach PJ; Du W; Johnson J; Kudchadker RJ; Kuban DA
Am J Clin Oncol; 2018 Jun; 41(6):558-567. PubMed ID: 27635624
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
12. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
13. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
14. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
15. Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.
Di Franco R; Borzillo V; Ravo V; Ametrano G; Falivene S; Cammarota F; Rossetti S; Romano FJ; D'Aniello C; Cavaliere C; Iovane G; Piscitelli R; Berretta M; Muto P; Facchini G
Oncotarget; 2017 Mar; 8(10):17383-17395. PubMed ID: 28129649
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and natural history of anorectal sequelae following radiation therapy for carcinoma of the prostate.
Yeoh EK; Holloway RH; Fraser RJ; Botten RJ; Di Matteo AC; Butters J
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):e593-9. PubMed ID: 22836050
[TBL] [Abstract][Full Text] [Related]
17. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
[TBL] [Abstract][Full Text] [Related]
19. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
Madsen BL; Hsi RA; Pham HT; Fowler JF; Esagui L; Corman J
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1099-105. PubMed ID: 17336216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
